欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2003, Vol. 8 ›› Issue (5): 585-590.

• 研究原著 • 上一篇    下一篇

拓扑替康单药治疗难治性小细胞肺癌的临床评价

高文斌, 尹良伟, 王怀瑾, 王丽双, 王蕾   

  1. 大连市肿瘤医院肿瘤五病区,大连 116038,辽宁
  • 收稿日期:2003-02-18 修回日期:2003-03-26 出版日期:2003-10-26 发布日期:2020-11-19
  • 通讯作者: 高文斌,男,本科,主治医师,主要从事于肿瘤内科化疗和肿瘤介入治疗。Tel:0411-6898146   E-mail:wenbingao@yahoo.com.cn

Clinical evaluation of topotecan in treatment ofPatients with hard-cured small celllung cancer

GAO Wen-Bin, YINLIang-Wei, WANG Huai-Jin, WANGLI-Shuang, WANG Lei   

  1. Fifth Ward,Dalian Tumor Hospital,Dalian 116038,liaoning,China
  • Received:2003-02-18 Revised:2003-03-26 Online:2003-10-26 Published:2020-11-19

摘要: 目的 观察拓扑替康单药治疗难治性小细胞肺癌(SCLC)的疗效及其毒副反应。方法 难治性SCLC 患者 38 例,采用拓扑替康(topotecan,T,金喜素)1.2 mg·m-2·d-1,静脉滴注,d1~ 5,21 d 为 1 个周期,共 2~ 3 个周期 。结果 拓扑替康单药的有效率为 23.68 %(9/38),其中局限型病例的有效率为36.36%(4/11),广泛型为 18.52%(5/27),组间比较无统计学差异(χ2=0.567,P>0.05)。毒副反应以血液毒性为主,白细胞和血小板Ⅲ +Ⅳ度下降病例为 23.68%,26.32%,血红蛋白未见明显的毒副反应,其他反应轻微。结论 拓扑替康单药治疗难治性SCLC 具有较好的疗效并可以作为SCLC 的二线治疗药物应用 。

关键词: 药效学, 拓扑替康, 小细胞肺癌, 难治性, 化疗

Abstract: AIM: To observe the efficacy and safety of topotecan on hard-cured small celllung cancer(SCLC).METHODS: 38Patients of hard-cured SCLC were treated with topotecan 1.2 mg·m-2·d-1(iv)on d1~ 5and 21 days a cycle and the treatmentlasted for 2-3 cycles.RESULTS: The response rate to topotecan was 23.68% (9/38)including 36.36% (4/11)inlimited type and 18.52%(5/27)in extensive type.There were no statistical differences between them (χ2=0.567,P>0.05).The main side reactions were neutropenia and thrombocytopenia with incidence of 23.68% and 26.32%in gradeⅢ+Ⅳ,respectively,but without side reaction to hemoglobin.CONCLUSION: Topotecan is an effective agent in the treatment ofPatients with SCLC.

Key words: pharmacodynamoics, topotecan, small celllung cancer, hard-cured, chemotherapy

中图分类号: